ClinicalTrials.gg
TerminatedNCT00319228Updated Oct 7, 2026Results posted

Safety, Pharmacokinetics and Efficacy of an ATIII Concentrate

A Phase 2/3 interventional study of Plasma-derived AT-III concentrate in Antithrombin III Deficiency, sponsored by Instituto Grifols, S.A.. Terminated. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Instituto Grifols, S.A. (part of Grifols) · Phase 2/3, Interventional, and Prevention

How we know

Why this study was terminated
Due to recruitment challenges during the trial, this study was terminated early by the Sponsor.
Updated Oct 7, 2026Now TerminatedResults posted+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Study summary

To assess the safety, pharmacokinetics and efficacy of a plasma-derived AT-III concentrate in the treatment of subjects with congenital AT-III deficiency.

Read the detailed description

This study was a prospective, unblinded, non-randomized, open-label, multi-center Phase II/III study with 2 segments, i.e. a PK evaluation (Segment I), and an assessment of prophylaxis in surgical interventions and pregnancy/delivery, (Segment II). During the PK segment (Segment I), the subjects were to be remained on their current anticoagulation therapy except for subjects on heparin therapy where a wash-out period of at least 5 half-lives was to be required. In total, 15 subjects with congenital ATIII Deficiency were to be enrolled for the PK assessment (Segment I).

For Segment II, fifteen episodes were to be treated. Recruitment of individual subjects with high risk for venous thrombosis for Segment II of this study was necessary because of the rarity of Antithrombin deficiency in the population.

02

Conditions studied

  • Antithrombin III Deficiency

Keywords

  • AT-III deficiency
  • AT-III concentrate
  • Bleeding disorders
  • Blood disorders
03

In context

Hemostatic Disorders

361 studies on the registry are indexed under Hemostatic Disorders; 65 are open to participants now.

This study's enrollment of 3 is below the median of 60 across 171 interventional studies indexed under Hemostatic Disorders.

Browse Hemostatic Disorders studies →

Lead sponsor

Instituto Grifols, S.A. is the lead sponsor of 24 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 7, 2026. See what changed

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Congenital ATIII deficiency documented by determination of plasma levels of ATIII off all therapies. Specifically, the baseline levels of ATIII activity should have been equal to or less than 60%.
  • Age >12 years with a body weight of no less than 30 kg.
  • Subject must not have participated in another study for at least 30 days.
  • For Segment II, enrollment required a pregnancy/delivery or a surgical procedure (it should have been a major surgery although data from a minor surgery would also have been collected).
  • For Segment II only, documented personal history of major thromboembolic or thrombotic event.
  • , , , HAV and PARVO B19 status known prior to entry.
  • The subject must have been willing to comply with all aspects of the protocol, including blood sampling, for the duration of the study.
  • The subject signed an form (if at least 18 years old), or the subject's parent or legal guardian signed the informed consent form. Subjects below the age of 18 years were asked to sign an assent form. All consent and assent forms must have been approved in advance by the Institutional Review Board of the investigator's institution.
  • Patients with heparin-associated thrombocytopenia who required anticoagulation with non-heparin containing drugs were eligible if they could be safely transitioned during the for the Segment I PK study.
  • If pregnant, a woman must have been Parvo B19 IgG antibody positive.

Exclusion criteria

Exclusion Criteria:

  • Acquired deficiency of ATIII.
  • Subject who received concomitant treatment for thrombophilic disorders other than ATIII deficiency.
  • History of anaphylactic reaction(s) to blood or blood components.
  • Allergies to .
  • Liver function tests >/= 2.5 X
  • Serum creatinine >1.2 X ULN.
  • Urine >/= 2+ protein with urine dipstick test.
  • The subject was known to have abused alcohol or illicit drugs within the past 12 months.
  • The subject was unlikely to adhere to the protocol requirements of the study or was likely to be uncooperative or unable to provide a storage serum sample at the screening visit.
  • Patients on heparin-treatment who, for clinical reasons, could not safely be discontinued from heparin therapy during the PK segment.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Antithrombin III

    Drug: Plasma-derived AT-III concentrate

Interventions

  • DrugPlasma-derived AT-III concentrate

    Segment I: A single dose IV infusion of 50 IU/kg of ATIII-DAF/DI was administered to each patient. Segment II: A single dose or multiple doses depending on the subject's ATIII plasma levels and patient's specific treatment plan.

06

What researchers measure

Primary outcomes

  1. Assess the Pharmacokinetic Profile (T1/2) of Anbinex® Using Chromogenic Methods for Subjects Enrolled in Segment 1 of the Study.

    Assess the pharmacokinetic profile of parameters T1/2, area under the curve \[AUC\], mean residence time \[MRT\], volume of distribution at steady-state \[Vdss\], and clearance of substrate \[CL\] of AT-III in congenital AT-III deficient patients. AT PK parameters were determined by two methods: chromogenic to determine the activity of AT, and radial immunodiffusion to determine the antigen of AT. Chromogenic assay data reported in % was used for pharmacokinetic parameter estimation. Pharmacokinetic parameters were estimated using noncompartmental analysis of antithrombin concentration-time data collected from Day 1 through Day 16. Reported values are derived estimates based on the concentration-time profile and may include extrapolation beyond the last measurable concentration, where applicable. Due to the small number of subjects in Segment I, no data integration across the 2 subjects nor statistical analysis of these PK parameters were performed.

    Time frame: 30 minutes before the first infusion on Day 1 through Day 16 (pharmacokinetic parameters estimated using concentration-time data collected during this period)

  2. Assess the Pharmacokinetic Profile (AUC) of Anbinex® Using Chromogenic Methods for Subjects Enrolled in Segment 1 of the Study.

    Assess the pharmacokinetic profile of parameters T1/2, area under the curve \[AUC\], mean residence time \[MRT\], volume of distribution at steady-state \[Vdss\], and clearance of substrate \[CL\] of AT-III in congenital AT-III deficient patients. AT PK parameters were determined by two methods: chromogenic to determine the activity of AT, and radial immunodiffusion to determine the antigen of AT. Chromogenic assay data reported in % was used for pharmacokinetic parameter estimation. Due to the small number of subjects in Segment I, no data integration across the 2 subjects nor statistical analysis of these PK parameters were performed.

    Time frame: 30 minutes before the first infusion on Day 1 to Day 16.

  3. Assess the Pharmacokinetic Profile (MRT) of Anbinex® Using Chromogenic Methods for Subjects Enrolled in Segment 1 of the Study.

    Assess the pharmacokinetic profile of parameters T1/2, area under the curve \[AUC\], mean residence time \[MRT\], volume of distribution at steady-state \[Vdss\], and clearance of substrate \[CL\] of AT-III in congenital AT-III deficient patients. AT PK parameters were determined by two methods: chromogenic to determine the activity of AT, and radial immunodiffusion to determine the antigen of AT. Chromogenic assay data reported in % was used for pharmacokinetic parameter estimation. Pharmacokinetic parameters were estimated using noncompartmental analysis of antithrombin concentration-time data collected from Day 1 through Day 16. Reported values are derived estimates based on the concentration-time profile and may include extrapolation beyond the last measurable concentration, where applicable. Due to the small number of subjects in Segment I, no data integration across the 2 subjects nor statistical analysis of these PK parameters were performed.

    Time frame: 30 minutes before the first infusion on Day 1 through Day 16 (pharmacokinetic parameters estimated using concentration-time data collected during this period)

  4. Assess the Pharmacokinetic Profile (Vdss) of Anbinex® Using Chromogenic Methods for Subjects Enrolled in Segment 1 of the Study.

    Assess the pharmacokinetic profile of parameters T1/2, area under the curve \[AUC\], mean residence time \[MRT\], volume of distribution at steady-state \[Vdss\], and clearance of substrate \[CL\] of AT-III in congenital AT-III deficient patients. AT PK parameters were determined by two methods: chromogenic to determine the activity of AT, and radial immunodiffusion to determine the antigen of AT. Chromogenic assay data reported in % was used for pharmacokinetic parameter estimation. Due to the small number of subjects in Segment I, no data integration across the 2 subjects nor statistical analysis of these PK parameters were performed.

    Time frame: 30 minutes before the first infusion on Day 1 to Day 16.

  5. Assess the Pharmacokinetic Profile (CL) of Anbinex® Using Chromogenic Methods for Subjects Enrolled in Segment 1 of the Study.

    Assess the pharmacokinetic profile of parameters T1/2, area under the curve \[AUC\], mean residence time \[MRT\], volume of distribution at steady-state \[Vdss\], and clearance of substrate \[CL\] of AT-III in congenital AT-III deficient patients. AT PK parameters were determined by two methods: chromogenic to determine the activity of AT, and radial immunodiffusion to determine the antigen of AT. Chromogenic assay data reported in % was used for pharmacokinetic parameter estimation. Due to the small number of subjects in Segment I, no data integration across the 2 subjects nor statistical analysis of these PK parameters were performed.

    Time frame: 30 minutes before the first infusion on Day 1 to Day 16.

  6. Assess the Pharmacokinetic Profile (T1/2) of Anbinex® Using Radial Immunodiffusion Methods for Subjects Enrolled in Segment 1 of the Study.

    Assess the pharmacokinetic profile of T1/2, area under the curve \[AUC\], mean residence time \[MRT\], volume of distribution at steady-state \[Vdss\], and clearance of substrate \[CL\]) of AT-III in congenital AT-III deficient patients. AT PK parameters were determined by two methods: chromogenic to determine the activity of AT, and radial immunodiffusion to determine the antigen of AT. Pharmacokinetic parameters were estimated using noncompartmental analysis of antithrombin concentration-time data collected from Day 1 through Day 16. Reported values are derived estimates based on the concentration-time profile and may include extrapolation beyond the last measurable concentration, where applicable. Due to the small number of subjects in Segment I, no data integration across the 2 subjects nor statistical analysis of these PK parameters were performed.

    Time frame: 30 minutes before the first infusion on Day 1 through Day 16 (pharmacokinetic parameters estimated using concentration-time data collected during this period)

  7. Assess the Pharmacokinetic Profile (AUC) of Anbinex® Using Radial Immunodiffusion Methods for Subjects Enrolled in Segment 1 of the Study.

    Assess the pharmacokinetic profile of T1/2, area under the curve \[AUC\], mean residence time \[MRT\], volume of distribution at steady-state \[Vdss\], and clearance of substrate \[CL\]) of AT-III in congenital AT-III deficient patients. AT PK parameters were determined by two methods: chromogenic to determine the activity of AT, and radial immunodiffusion to determine the antigen of AT. Due to the small number of subjects in Segment I, no data integration across the 2 subjects nor statistical analysis of these PK parameters were performed.

    Time frame: 30 minutes before the first infusion on Day 1 to Day 16.

  8. Assess the Pharmacokinetic Profile (MRT) of Anbinex® Using Radial Immunodiffusion Methods for Subjects Enrolled in Segment 1 of the Study.

    Assess the pharmacokinetic profile of T1/2, area under the curve \[AUC\], mean residence time \[MRT\], volume of distribution at steady-state \[Vdss\], and clearance of substrate \[CL\]) of AT-III in congenital AT-III deficient patients. AT PK parameters were determined by two methods: chromogenic to determine the activity of AT, and radial immunodiffusion to determine the antigen of AT. Pharmacokinetic parameters were estimated using noncompartmental analysis of antithrombin concentration-time data collected from Day 1 through Day 16. Reported values are derived estimates based on the concentration-time profile and may include extrapolation beyond the last measurable concentration, where applicable. Due to the small number of subjects in Segment I, no data integration across the 2 subjects nor statistical analysis of these PK parameters were performed.

    Time frame: 30 minutes before the first infusion on Day 1 through Day 16 (pharmacokinetic parameters estimated using concentration-time data collected during this period)

  9. Assess the Pharmacokinetic Profile (Vdss) of Anbinex® Using Radial Immunodiffusion Methods for Subjects Enrolled in Segment 1 of the Study.

    Assess the pharmacokinetic profile of T1/2, area under the curve \[AUC\], mean residence time \[MRT\], volume of distribution at steady-state \[Vdss\], and clearance of substrate \[CL\]) of AT-III in congenital AT-III deficient patients. AT PK parameters were determined by two methods: chromogenic to determine the activity of AT, and radial immunodiffusion to determine the antigen of AT. Due to the small number of subjects in Segment I, no data integration across the 2 subjects nor statistical analysis of these PK parameters were performed.

    Time frame: 30 minutes before the first infusion on Day 1 to Day 16.

  10. Assess the Pharmacokinetic Profile (CL) of Anbinex® Using Radial Immunodiffusion Methods for Subjects Enrolled in Segment 1 of the Study.

    Assess the pharmacokinetic profile of T1/2, area under the curve \[AUC\], mean residence time \[MRT\], volume of distribution at steady-state \[Vdss\], and clearance of substrate \[CL\]) of AT-III in congenital AT-III deficient patients. AT PK parameters were determined by two methods: chromogenic to determine the activity of AT, and radial immunodiffusion to determine the antigen of AT. Due to the small number of subjects in Segment I, no data integration across the 2 subjects nor statistical analysis of these PK parameters were performed.

    Time frame: 30 minutes before the first infusion on Day 1 to Day 16.

07

Results

Posted Oct 7, 2026

Participant flow

Three unique subjects in the United States were enrolled in Study IG401.

Participant flow — Overall Study
MilestoneSegment ISegment II
Started23
Subjects who completed segment i and entered segment ii10
Subjects whose samples were assessed for pk20
Total number of clinical events03
Parturition02
Surgical removal of compound melanocytic nevus01
Completed23
Not completed00

Outcome measures

PrimaryAssess the Pharmacokinetic Profile (T1/2) of Anbinex® Using Chromogenic Methods for Subjects Enrolled in Segment 1 of the Study.

Assess the pharmacokinetic profile of parameters T1/2, area under the curve \[AUC\], mean residence time \[MRT\], volume of distribution at steady-state \[Vdss\], and clearance of substrate \[CL\] of AT-III in congenital AT-III deficient patients. AT PK parameters were determined by two methods: chromogenic to determine the activity of AT, and radial immunodiffusion to determine the antigen of AT. Chromogenic assay data reported in % was used for pharmacokinetic parameter estimation. Pharmacokinetic parameters were estimated using noncompartmental analysis of antithrombin concentration-time data collected from Day 1 through Day 16. Reported values are derived estimates based on the concentration-time profile and may include extrapolation beyond the last measurable concentration, where applicable. Due to the small number of subjects in Segment I, no data integration across the 2 subjects nor statistical analysis of these PK parameters were performed.

Time frame:
30 minutes before the first infusion on Day 1 through Day 16 (pharmacokinetic parameters estimated using concentration-time data collected during this period)
Reported as:
Number · hours
Assess the Pharmacokinetic Profile (T1/2) of Anbinex® Using Chromogenic Methods for Subjects Enrolled in Segment 1 of the Study.
hoursSubject 1 Chromogenic UnadjustedSubject 1 Chromogenic Baseline AdjustedSubject 2 Chromogenic UnadjustedSubject 2 Chromogenic Baseline Adjusted
Assess the Pharmacokinetic Profile (T1/2) of Anbinex® Using Chromogenic Methods for Subjects Enrolled in Segment 1 of the Study.241.65421.63285.0597.13
PrimaryAssess the Pharmacokinetic Profile (AUC) of Anbinex® Using Chromogenic Methods for Subjects Enrolled in Segment 1 of the Study.

Assess the pharmacokinetic profile of parameters T1/2, area under the curve \[AUC\], mean residence time \[MRT\], volume of distribution at steady-state \[Vdss\], and clearance of substrate \[CL\] of AT-III in congenital AT-III deficient patients. AT PK parameters were determined by two methods: chromogenic to determine the activity of AT, and radial immunodiffusion to determine the antigen of AT. Chromogenic assay data reported in % was used for pharmacokinetic parameter estimation. Due to the small number of subjects in Segment I, no data integration across the 2 subjects nor statistical analysis of these PK parameters were performed.

Time frame:
30 minutes before the first infusion on Day 1 to Day 16.
Reported as:
Number · h*mg/dL
Assess the Pharmacokinetic Profile (AUC) of Anbinex® Using Chromogenic Methods for Subjects Enrolled in Segment 1 of the Study.
h*mg/dLSubject 1 Chromogenic UnadjustedSubject 1 Chromogenic Baseline AdjustedSubject 2 Chromogenic UnadjustedSubject 2 Chromogenic Baseline Adjusted
Assess the Pharmacokinetic Profile (AUC) of Anbinex® Using Chromogenic Methods for Subjects Enrolled in Segment 1 of the Study.44974.513175.2448610.546788.75
PrimaryAssess the Pharmacokinetic Profile (MRT) of Anbinex® Using Chromogenic Methods for Subjects Enrolled in Segment 1 of the Study.

Assess the pharmacokinetic profile of parameters T1/2, area under the curve \[AUC\], mean residence time \[MRT\], volume of distribution at steady-state \[Vdss\], and clearance of substrate \[CL\] of AT-III in congenital AT-III deficient patients. AT PK parameters were determined by two methods: chromogenic to determine the activity of AT, and radial immunodiffusion to determine the antigen of AT. Chromogenic assay data reported in % was used for pharmacokinetic parameter estimation. Pharmacokinetic parameters were estimated using noncompartmental analysis of antithrombin concentration-time data collected from Day 1 through Day 16. Reported values are derived estimates based on the concentration-time profile and may include extrapolation beyond the last measurable concentration, where applicable. Due to the small number of subjects in Segment I, no data integration across the 2 subjects nor statistical analysis of these PK parameters were performed.

Time frame:
30 minutes before the first infusion on Day 1 through Day 16 (pharmacokinetic parameters estimated using concentration-time data collected during this period)
Reported as:
Number · hours
Assess the Pharmacokinetic Profile (MRT) of Anbinex® Using Chromogenic Methods for Subjects Enrolled in Segment 1 of the Study.
hoursSubject 1 Chromogenic UnadjustedSubject 1 Chromogenic Baseline AdjustedSubject 2 Chromogenic UnadjustedSubject 2 Chromogenic Baseline Adjusted
Assess the Pharmacokinetic Profile (MRT) of Anbinex® Using Chromogenic Methods for Subjects Enrolled in Segment 1 of the Study.434.03385.31475.74171.44
PrimaryAssess the Pharmacokinetic Profile (Vdss) of Anbinex® Using Chromogenic Methods for Subjects Enrolled in Segment 1 of the Study.

Assess the pharmacokinetic profile of parameters T1/2, area under the curve \[AUC\], mean residence time \[MRT\], volume of distribution at steady-state \[Vdss\], and clearance of substrate \[CL\] of AT-III in congenital AT-III deficient patients. AT PK parameters were determined by two methods: chromogenic to determine the activity of AT, and radial immunodiffusion to determine the antigen of AT. Chromogenic assay data reported in % was used for pharmacokinetic parameter estimation. Due to the small number of subjects in Segment I, no data integration across the 2 subjects nor statistical analysis of these PK parameters were performed.

Time frame:
30 minutes before the first infusion on Day 1 to Day 16.
Reported as:
Number · IU/kg/[mg/dL]
Assess the Pharmacokinetic Profile (Vdss) of Anbinex® Using Chromogenic Methods for Subjects Enrolled in Segment 1 of the Study.
IU/kg/[mg/dL]Subject 1 Chromogenic UnadjustedSubject 1 Chromogenic Baseline AdjustedSubject 2 Chromogenic UnadjustedSubject 2 Chromogenic Baseline Adjusted
Assess the Pharmacokinetic Profile (Vdss) of Anbinex® Using Chromogenic Methods for Subjects Enrolled in Segment 1 of the Study.0.48256.06740.48931.2627
PrimaryAssess the Pharmacokinetic Profile (CL) of Anbinex® Using Chromogenic Methods for Subjects Enrolled in Segment 1 of the Study.

Assess the pharmacokinetic profile of parameters T1/2, area under the curve \[AUC\], mean residence time \[MRT\], volume of distribution at steady-state \[Vdss\], and clearance of substrate \[CL\] of AT-III in congenital AT-III deficient patients. AT PK parameters were determined by two methods: chromogenic to determine the activity of AT, and radial immunodiffusion to determine the antigen of AT. Chromogenic assay data reported in % was used for pharmacokinetic parameter estimation. Due to the small number of subjects in Segment I, no data integration across the 2 subjects nor statistical analysis of these PK parameters were performed.

Time frame:
30 minutes before the first infusion on Day 1 to Day 16.
Reported as:
Number · IU/kg/[hr*mg/dL]
Assess the Pharmacokinetic Profile (CL) of Anbinex® Using Chromogenic Methods for Subjects Enrolled in Segment 1 of the Study.
IU/kg/[hr*mg/dL]Subject 1 Chromogenic UnadjustedSubject 1 Chromogenic Baseline AdjustedSubject 2 Chromogenic UnadjustedSubject 2 Chromogenic Baseline Adjusted
Assess the Pharmacokinetic Profile (CL) of Anbinex® Using Chromogenic Methods for Subjects Enrolled in Segment 1 of the Study.0.00110.01570.00100.0074
PrimaryAssess the Pharmacokinetic Profile (T1/2) of Anbinex® Using Radial Immunodiffusion Methods for Subjects Enrolled in Segment 1 of the Study.

Assess the pharmacokinetic profile of T1/2, area under the curve \[AUC\], mean residence time \[MRT\], volume of distribution at steady-state \[Vdss\], and clearance of substrate \[CL\]) of AT-III in congenital AT-III deficient patients. AT PK parameters were determined by two methods: chromogenic to determine the activity of AT, and radial immunodiffusion to determine the antigen of AT. Pharmacokinetic parameters were estimated using noncompartmental analysis of antithrombin concentration-time data collected from Day 1 through Day 16. Reported values are derived estimates based on the concentration-time profile and may include extrapolation beyond the last measurable concentration, where applicable. Due to the small number of subjects in Segment I, no data integration across the 2 subjects nor statistical analysis of these PK parameters were performed.

Time frame:
30 minutes before the first infusion on Day 1 through Day 16 (pharmacokinetic parameters estimated using concentration-time data collected during this period)
Reported as:
Number · hours
Assess the Pharmacokinetic Profile (T1/2) of Anbinex® Using Radial Immunodiffusion Methods for Subjects Enrolled in Segment 1 of the Study.
hoursSubject 1 Radial Immunodiffusions UnadjustedSubject 1 Radial Immunodiffusions Baseline AdjustedSubject 2 Radial Immunodiffusions UnadjustedSubject 2 Radial Immunodiffusions Baseline Adjusted
Assess the Pharmacokinetic Profile (T1/2) of Anbinex® Using Radial Immunodiffusion Methods for Subjects Enrolled in Segment 1 of the Study.249.5448.75244.0669.11
PrimaryAssess the Pharmacokinetic Profile (AUC) of Anbinex® Using Radial Immunodiffusion Methods for Subjects Enrolled in Segment 1 of the Study.

Assess the pharmacokinetic profile of T1/2, area under the curve \[AUC\], mean residence time \[MRT\], volume of distribution at steady-state \[Vdss\], and clearance of substrate \[CL\]) of AT-III in congenital AT-III deficient patients. AT PK parameters were determined by two methods: chromogenic to determine the activity of AT, and radial immunodiffusion to determine the antigen of AT. Due to the small number of subjects in Segment I, no data integration across the 2 subjects nor statistical analysis of these PK parameters were performed.

Time frame:
30 minutes before the first infusion on Day 1 to Day 16.
Reported as:
Number · h*mg/dL
Assess the Pharmacokinetic Profile (AUC) of Anbinex® Using Radial Immunodiffusion Methods for Subjects Enrolled in Segment 1 of the Study.
h*mg/dLSubject 1 Radial Immunodiffusions UnadjustedSubject 1 Radial Immunodiffusions Baseline AdjustedSubject 2 Radial Immunodiffusions UnadjustedSubject 2 Radial Immunodiffusions Baseline Adjusted
Assess the Pharmacokinetic Profile (AUC) of Anbinex® Using Radial Immunodiffusion Methods for Subjects Enrolled in Segment 1 of the Study.14591.551066.9214697.162422.27
PrimaryAssess the Pharmacokinetic Profile (MRT) of Anbinex® Using Radial Immunodiffusion Methods for Subjects Enrolled in Segment 1 of the Study.

Assess the pharmacokinetic profile of T1/2, area under the curve \[AUC\], mean residence time \[MRT\], volume of distribution at steady-state \[Vdss\], and clearance of substrate \[CL\]) of AT-III in congenital AT-III deficient patients. AT PK parameters were determined by two methods: chromogenic to determine the activity of AT, and radial immunodiffusion to determine the antigen of AT. Pharmacokinetic parameters were estimated using noncompartmental analysis of antithrombin concentration-time data collected from Day 1 through Day 16. Reported values are derived estimates based on the concentration-time profile and may include extrapolation beyond the last measurable concentration, where applicable. Due to the small number of subjects in Segment I, no data integration across the 2 subjects nor statistical analysis of these PK parameters were performed.

Time frame:
30 minutes before the first infusion on Day 1 through Day 16 (pharmacokinetic parameters estimated using concentration-time data collected during this period)
Reported as:
Number · hours
Assess the Pharmacokinetic Profile (MRT) of Anbinex® Using Radial Immunodiffusion Methods for Subjects Enrolled in Segment 1 of the Study.
hoursSubject 1 Radial Immunodiffusions UnadjustedSubject 1 Radial Immunodiffusions Baseline AdjustedSubject 2 Radial Immunodiffusions UnadjustedSubject 2 Radial Immunodiffusions Baseline Adjusted
Assess the Pharmacokinetic Profile (MRT) of Anbinex® Using Radial Immunodiffusion Methods for Subjects Enrolled in Segment 1 of the Study.428.0269.33392.25126.16
PrimaryAssess the Pharmacokinetic Profile (Vdss) of Anbinex® Using Radial Immunodiffusion Methods for Subjects Enrolled in Segment 1 of the Study.

Assess the pharmacokinetic profile of T1/2, area under the curve \[AUC\], mean residence time \[MRT\], volume of distribution at steady-state \[Vdss\], and clearance of substrate \[CL\]) of AT-III in congenital AT-III deficient patients. AT PK parameters were determined by two methods: chromogenic to determine the activity of AT, and radial immunodiffusion to determine the antigen of AT. Due to the small number of subjects in Segment I, no data integration across the 2 subjects nor statistical analysis of these PK parameters were performed.

Time frame:
30 minutes before the first infusion on Day 1 to Day 16.
Reported as:
Number · IU/kg/[mg/dL]
Assess the Pharmacokinetic Profile (Vdss) of Anbinex® Using Radial Immunodiffusion Methods for Subjects Enrolled in Segment 1 of the Study.
IU/kg/[mg/dL]Subject 1 Radial Immunodiffusions UnadjustedSubject 1 Radial Immunodiffusions Baseline AdjustedSubject 2 Radial Immunodiffusions UnadjustedSubject 2 Radial Immunodiffusions Baseline Adjusted
Assess the Pharmacokinetic Profile (Vdss) of Anbinex® Using Radial Immunodiffusion Methods for Subjects Enrolled in Segment 1 of the Study.1.46673.24921.33442.6042
PrimaryAssess the Pharmacokinetic Profile (CL) of Anbinex® Using Radial Immunodiffusion Methods for Subjects Enrolled in Segment 1 of the Study.

Assess the pharmacokinetic profile of T1/2, area under the curve \[AUC\], mean residence time \[MRT\], volume of distribution at steady-state \[Vdss\], and clearance of substrate \[CL\]) of AT-III in congenital AT-III deficient patients. AT PK parameters were determined by two methods: chromogenic to determine the activity of AT, and radial immunodiffusion to determine the antigen of AT. Due to the small number of subjects in Segment I, no data integration across the 2 subjects nor statistical analysis of these PK parameters were performed.

Time frame:
30 minutes before the first infusion on Day 1 to Day 16.
Reported as:
Number · IU/kg/[hr*mg/dL]
Assess the Pharmacokinetic Profile (CL) of Anbinex® Using Radial Immunodiffusion Methods for Subjects Enrolled in Segment 1 of the Study.
IU/kg/[hr*mg/dL]Subject 1 Radial Immunodiffusions UnadjustedSubject 1 Radial Immunodiffusions Baseline AdjustedSubject 2 Radial Immunodiffusions UnadjustedSubject 2 Radial Immunodiffusions Baseline Adjusted
Assess the Pharmacokinetic Profile (CL) of Anbinex® Using Radial Immunodiffusion Methods for Subjects Enrolled in Segment 1 of the Study.0.00340.04690.00340.0206

Adverse events

Collected over Up to Month 6. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Segment I0/2 (0%)1/2 (50%)2/2 (100%)
Segment II0/2 (0%)0/2 (0%)1/2 (50%)
Most frequent serious events
Most frequent serious events
EventSegment ISegment II
CellulitisInfections and infestations1/20/2
Most frequent other events
Most frequent other events
EventSegment ISegment II
FatigueGeneral disorders1/21/2
CellulitisInfections and infestations1/20/2

Baseline characteristics

The intent-to-treat (ITT) population includes all subjects who were enrolled and received at least 1 ATIII-DAF/DI infusion. Segment II includes 1 subject who enrolled in both Segments I and II. Segment II also includes 1 subject who was assigned 2 subject numbers due to 2 clinical events of pregnancy.

Age, Continuous
Age, Continuous(years)Segment ISegment IITotal
Mean26.0 ± 1.4136.0 ± 6.2433 ± 11.3
Sex: Female, Male
Sex: Female, Male(Participants)Segment ISegment IITotal
Female123
Male112
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Segment ISegment IITotal
Hispanic or Latino000
Not Hispanic or Latino235
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Segment ISegment IITotal
Caucasian235
African-American000
American Indian000
Asian000
Pacific Islander000
Other000
08

Study locations

No study locations are listed for this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Apr 2008 to primary completion in Dec 2011, 44 months.

Results were first posted in Oct 2026, 14 years 10 months after primary completion.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 7, 2026: start Jan 2006 → Apr 2008, primary completion Dec 2028 → Dec 2011 and completion Mar 2029 → Dec 2011.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2006
First posted
Apr 27, 2006
StartActual
Apr 15, 2008was Jan 2006
Primary completionActual
Dec 2011was Dec 2028
CompletionActual
Dec 16, 2011was Mar 2029
Results first posted
Oct 7, 2026
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated Due to recruitment challenges during the trial, this study was terminated early by the Sponsor.
changed Oct 7, 2026
Results
Results posted
posted Oct 7, 2026
Start date
Jan 2006→Apr 15, 2008
Oct 7, 2026
Primary completion
Dec 2028→Dec 2011 (actual)
Oct 7, 2026
Study completion
Mar 2029→Dec 16, 2011 (actual)
Oct 7, 2026
Enrollment
30 (estimated)→3 (actual)
Oct 7, 2026
Eligibility
7 inclusion criteria edited, 1 added, 1 removed; 4 exclusion criteria edited, 1 removed
What changed in the criteria
Inclusion criteria
  • EditedCongenital ATIII deficiency documented by determination of plasma levels of ATIII off all therapies. Specifically, the baseline levels of ATIII activity should behave been equal to or less than 60%.
  • AddedSubject must not have participated in another investigational study for at least 30 days.
  • EditedHave not participated in another investigational study for at least 30 days. For Segment II, enrollment requiresrequired a pregnancy/delivery or a surgical procedure (it should behave been a major surgery although data from a minor surgery willwould also behave been collected).
  • EditedDocumentedFor Segment II only, documented personal history of major thromboembolic or thrombotic event.
  • RemovedMale or female
  • EditedThe subject ismust have been willing to comply with all aspects of the protocol, including blood sampling, for the duration of the study.
  • EditedThe subject has signed an informed consent form (if at least 18 years old), or the subject's parent or legal guardian has signed the informed consent form. Subjects below the age of 18 years will also bewere asked to sign an assent form. All consent and assent forms must behave been approved in advance by the Institutional Review Board of the investigator's institution.
  • EditedPatients with heparin-associated thrombocytopenia who requirerequired anticoagulation with non-heparin containing drugs will bewere eligible if they cancould be safely transitioned during the washout period for the Segment I PK study.
  • EditedIf pregnant, a woman must behave been Parvo B19 IgG antibody positive.
Exclusion criteria
  • EditedReceivingSubject who received concomitant treatment for thrombophilic disorders other than ATIII deficiency.
  • RemovedInability or unwillingness to comply with the protocol requirements.
  • EditedThe subject iswas known to have abused alcohol or illicit drugs within the past 12 months.
  • EditedThe subject iswas unlikely to adhere to the protocol requirements of the study or iswas likely to be uncooperative or unable to provide a storage serum sample at the screening visit.
  • EditedPatients on heparin-treatment who, for clinical reasons, cannotcould not safely be discontinued from heparin therapy during the PK segment.
Oct 7, 2026
Primary outcomes
10 added, 4 removed
What changed in the outcomes
  • AddedAssess the Pharmacokinetic Profile (T1/2) of Anbinex® Using Chromogenic Methods for Subjects Enrolled in Segment 1 of the Study.Time frame: 30 minutes before the first infusion on Day 1 through Day 16 (pharmacokinetic parameters estimated using concentration-time data collected during this period)
  • AddedAssess the Pharmacokinetic Profile (AUC) of Anbinex® Using Chromogenic Methods for Subjects Enrolled in Segment 1 of the Study.Time frame: 30 minutes before the first infusion on Day 1 to Day 16.
  • AddedAssess the Pharmacokinetic Profile (MRT) of Anbinex® Using Chromogenic Methods for Subjects Enrolled in Segment 1 of the Study.Time frame: 30 minutes before the first infusion on Day 1 through Day 16 (pharmacokinetic parameters estimated using concentration-time data collected during this period)
  • AddedAssess the Pharmacokinetic Profile (Vdss) of Anbinex® Using Chromogenic Methods for Subjects Enrolled in Segment 1 of the Study.Time frame: 30 minutes before the first infusion on Day 1 to Day 16.
  • AddedAssess the Pharmacokinetic Profile (CL) of Anbinex® Using Chromogenic Methods for Subjects Enrolled in Segment 1 of the Study.Time frame: 30 minutes before the first infusion on Day 1 to Day 16.
  • AddedAssess the Pharmacokinetic Profile (T1/2) of Anbinex® Using Radial Immunodiffusion Methods for Subjects Enrolled in Segment 1 of the Study.Time frame: 30 minutes before the first infusion on Day 1 through Day 16 (pharmacokinetic parameters estimated using concentration-time data collected during this period)
  • AddedAssess the Pharmacokinetic Profile (AUC) of Anbinex® Using Radial Immunodiffusion Methods for Subjects Enrolled in Segment 1 of the Study.Time frame: 30 minutes before the first infusion on Day 1 to Day 16.
  • AddedAssess the Pharmacokinetic Profile (MRT) of Anbinex® Using Radial Immunodiffusion Methods for Subjects Enrolled in Segment 1 of the Study.Time frame: 30 minutes before the first infusion on Day 1 through Day 16 (pharmacokinetic parameters estimated using concentration-time data collected during this period)
  • AddedAssess the Pharmacokinetic Profile (Vdss) of Anbinex® Using Radial Immunodiffusion Methods for Subjects Enrolled in Segment 1 of the Study.Time frame: 30 minutes before the first infusion on Day 1 to Day 16.
  • AddedAssess the Pharmacokinetic Profile (CL) of Anbinex® Using Radial Immunodiffusion Methods for Subjects Enrolled in Segment 1 of the Study.Time frame: 30 minutes before the first infusion on Day 1 to Day 16.
  • RemovedThe primary objectives of this clinical study are to:Time frame: 2 years
  • RemovedAssess the pharmacokinetic (PK) profile of AT-III in congenital AT-III deficient patientsTime frame: 1 year
  • RemovedTo measure the in vivo recovery and half-life of AT-III.Time frame: 1 year
  • RemovedTo assess the clinical safety and tolerability of AT-III-DAF/DI.Time frame: 1 year
Oct 7, 2026
Secondary outcomes
1 removed
What changed in the outcomes
  • RemovedTo assess clinical efficacy by preventing thromboembolic or thrombotic events (prophylaxis) in individuals with congenital AT-III deficiency who are undergoing surgical procedures or who are pregnant and undergoing parturition.Time frame: 1 year
Oct 7, 2026
Sponsor
Grifols Biologicals, LLC→Instituto Grifols, S.A.
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Active, not recruiting→Terminated
    Why stopped Due to recruitment challenges during the trial, this study was terminated early by the Sponsor.
    Results posted
    Start date Jan 2006→Apr 15, 2008
    Primary completion Dec 2028→Dec 2011 (now actual)
    Study completion Mar 2029→Dec 16, 2011 (now actual)
    Enrollment 30 (estimated)→3 (actual)
    Eligibility 7 inclusion criteria edited, 1 added, 1 removed; 4 exclusion criteria edited, 1 removed
    What changed in the criteria
    Inclusion criteria
    • EditedCongenital ATIII deficiency documented by determination of plasma levels of ATIII off all therapies. Specifically, the baseline levels of ATIII activity should behave been equal to or less than 60%.
    • AddedSubject must not have participated in another investigational study for at least 30 days.
    • EditedHave not participated in another investigational study for at least 30 days. For Segment II, enrollment requiresrequired a pregnancy/delivery or a surgical procedure (it should behave been a major surgery although data from a minor surgery willwould also behave been collected).
    • EditedDocumentedFor Segment II only, documented personal history of major thromboembolic or thrombotic event.
    • RemovedMale or female
    • EditedThe subject ismust have been willing to comply with all aspects of the protocol, including blood sampling, for the duration of the study.
    • EditedThe subject has signed an informed consent form (if at least 18 years old), or the subject's parent or legal guardian has signed the informed consent form. Subjects below the age of 18 years will also bewere asked to sign an assent form. All consent and assent forms must behave been approved in advance by the Institutional Review Board of the investigator's institution.
    • EditedPatients with heparin-associated thrombocytopenia who requirerequired anticoagulation with non-heparin containing drugs will bewere eligible if they cancould be safely transitioned during the washout period for the Segment I PK study.
    • EditedIf pregnant, a woman must behave been Parvo B19 IgG antibody positive.
    Exclusion criteria
    • EditedReceivingSubject who received concomitant treatment for thrombophilic disorders other than ATIII deficiency.
    • RemovedInability or unwillingness to comply with the protocol requirements.
    • EditedThe subject iswas known to have abused alcohol or illicit drugs within the past 12 months.
    • EditedThe subject iswas unlikely to adhere to the protocol requirements of the study or iswas likely to be uncooperative or unable to provide a storage serum sample at the screening visit.
    • EditedPatients on heparin-treatment who, for clinical reasons, cannotcould not safely be discontinued from heparin therapy during the PK segment.
    Primary outcomes 10 added, 4 removed
    What changed in the outcomes
    • AddedAssess the Pharmacokinetic Profile (T1/2) of Anbinex® Using Chromogenic Methods for Subjects Enrolled in Segment 1 of the Study.Time frame: 30 minutes before the first infusion on Day 1 through Day 16 (pharmacokinetic parameters estimated using concentration-time data collected during this period)
    • AddedAssess the Pharmacokinetic Profile (AUC) of Anbinex® Using Chromogenic Methods for Subjects Enrolled in Segment 1 of the Study.Time frame: 30 minutes before the first infusion on Day 1 to Day 16.
    • AddedAssess the Pharmacokinetic Profile (MRT) of Anbinex® Using Chromogenic Methods for Subjects Enrolled in Segment 1 of the Study.Time frame: 30 minutes before the first infusion on Day 1 through Day 16 (pharmacokinetic parameters estimated using concentration-time data collected during this period)
    • AddedAssess the Pharmacokinetic Profile (Vdss) of Anbinex® Using Chromogenic Methods for Subjects Enrolled in Segment 1 of the Study.Time frame: 30 minutes before the first infusion on Day 1 to Day 16.
    • AddedAssess the Pharmacokinetic Profile (CL) of Anbinex® Using Chromogenic Methods for Subjects Enrolled in Segment 1 of the Study.Time frame: 30 minutes before the first infusion on Day 1 to Day 16.
    • AddedAssess the Pharmacokinetic Profile (T1/2) of Anbinex® Using Radial Immunodiffusion Methods for Subjects Enrolled in Segment 1 of the Study.Time frame: 30 minutes before the first infusion on Day 1 through Day 16 (pharmacokinetic parameters estimated using concentration-time data collected during this period)
    • AddedAssess the Pharmacokinetic Profile (AUC) of Anbinex® Using Radial Immunodiffusion Methods for Subjects Enrolled in Segment 1 of the Study.Time frame: 30 minutes before the first infusion on Day 1 to Day 16.
    • AddedAssess the Pharmacokinetic Profile (MRT) of Anbinex® Using Radial Immunodiffusion Methods for Subjects Enrolled in Segment 1 of the Study.Time frame: 30 minutes before the first infusion on Day 1 through Day 16 (pharmacokinetic parameters estimated using concentration-time data collected during this period)
    • AddedAssess the Pharmacokinetic Profile (Vdss) of Anbinex® Using Radial Immunodiffusion Methods for Subjects Enrolled in Segment 1 of the Study.Time frame: 30 minutes before the first infusion on Day 1 to Day 16.
    • AddedAssess the Pharmacokinetic Profile (CL) of Anbinex® Using Radial Immunodiffusion Methods for Subjects Enrolled in Segment 1 of the Study.Time frame: 30 minutes before the first infusion on Day 1 to Day 16.
    • RemovedThe primary objectives of this clinical study are to:Time frame: 2 years
    • RemovedAssess the pharmacokinetic (PK) profile of AT-III in congenital AT-III deficient patientsTime frame: 1 year
    • RemovedTo measure the in vivo recovery and half-life of AT-III.Time frame: 1 year
    • RemovedTo assess the clinical safety and tolerability of AT-III-DAF/DI.Time frame: 1 year
    Secondary outcomes 1 removed
    What changed in the outcomes
    • RemovedTo assess clinical efficacy by preventing thromboembolic or thrombotic events (prophylaxis) in individuals with congenital AT-III deficiency who are undergoing surgical procedures or who are pregnant and undergoing parturition.Time frame: 1 year
    Sponsor Grifols Biologicals, LLC→Instituto Grifols, S.A.
    + 5 other changes: index terms, verification date, description, arm descriptions and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT00319228
Responsible party
Sponsor
First posted
Apr 27, 2006
Start date
Apr 15, 2008
Primary completion
Dec 2011
Completion
Dec 16, 2011
Results posted
Oct 7, 2026
Last update
Oct 7, 2026

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion